Secondary Hyperparathyroidism: How Kidney Disease Affects the Glands and Calcium
Written by John P. Sabra, MD FACS
Updated May 2026
Educational only. This article is not medical advice. Always consult your physician about your individual situation.
Not every patient with a high PTH has a parathyroid adenoma. In secondary hyperparathyroidism, the parathyroid glands are doing exactly what they are supposed to do, but they are responding to a problem somewhere else in the body. Understanding the difference matters, because the treatment is entirely different.
Primary vs. Secondary: The Essential Distinction
In primary hyperparathyroidism, the parathyroid glands themselves are the problem. One or more glands produce too much PTH regardless of what the calcium level is. The result is chronically elevated calcium along with chronically elevated PTH. The treatment is surgical removal of the abnormal gland or glands.
In secondary hyperparathyroidism, the parathyroid glands are functioning appropriately. They are producing high levels of PTH because something else in the body is causing the calcium to run low or the phosphate to run high. The glands are responding to a real physiologic signal. The calcium is typically low or normal, not elevated. The treatment is directed at the underlying cause, not at the parathyroid glands themselves.
The most important consequence of this distinction is that secondary hyperparathyroidism is almost never treated with surgery. Removing the parathyroid glands in a patient whose calcium is already low would make the problem dramatically worse, not better. The glands are not malfunctioning. They are compensating.
The Two Main Causes of Secondary Hyperparathyroidism
Chronic kidney disease
Chronic kidney disease (CKD) is the most common cause of secondary hyperparathyroidism in the clinical population. As kidney function declines, several interrelated problems develop that together drive the parathyroid glands into overdrive:
- The kidneys lose the ability to activate vitamin D: active vitamin D (calcitriol) is produced by the kidneys from inactive vitamin D precursors. As kidney function falls, this conversion fails, and blood levels of active vitamin D drop.
- Calcium absorption from the intestine decreases: without adequate active vitamin D, the intestines cannot efficiently absorb calcium from food, so blood calcium tends to run low.
- Phosphate accumulates in the blood: the damaged kidneys cannot excrete phosphate normally, so serum phosphate rises. High phosphate directly stimulates PTH secretion and also binds calcium, lowering the free calcium level further.
- FGF23 rises: this hormone, produced by bone, further suppresses the production of active vitamin D in the kidneys, compounding the problem.
The net result is a parathyroid system working frantically to maintain normal calcium against multiple physiologic headwinds. PTH levels may rise to 5, 10, or even 20 times normal in advanced CKD. Over months and years, the chronically stimulated parathyroid glands grow larger (hyperplasia) and may eventually develop nodules that produce PTH autonomously, a condition called tertiary hyperparathyroidism.
Vitamin D deficiency
Vitamin D deficiency is the second major cause of secondary hyperparathyroidism and is far more common than most patients realize. Vitamin D is made in the skin from sun exposure and can be obtained in small amounts from food and supplements. Deficiency is common in patients who live in northern climates, have darker skin, are elderly, are obese, use strong sunscreen consistently, or have intestinal malabsorption disorders.
When vitamin D is deficient, calcium absorption from the gut falls. The calcium in the blood tends to drop, which stimulates the parathyroid glands to produce more PTH. The PTH pulls calcium out of the bones to keep blood calcium in the normal range. The result is a patient with normal blood calcium but elevated PTH and measurable bone loss over time.
Because vitamin D deficiency can mimic the biochemistry of mild primary hyperparathyroidism (elevated PTH with sometimes borderline-normal calcium), vitamin D status must always be assessed when hyperparathyroidism is being evaluated. Treating the deficiency with vitamin D supplementation often normalizes the PTH without any further intervention.
Every workup for hyperparathyroidism should include a 25-hydroxyvitamin D level. A patient with elevated PTH, normal or low-normal calcium, and low vitamin D likely has secondary hyperparathyroidism from vitamin D deficiency. Replacing the vitamin D and rechecking the labs is the appropriate first step. If PTH normalizes, no further workup is needed. If PTH remains elevated despite adequate vitamin D replacement, the possibility of primary hyperparathyroidism must then be reconsidered.
Less Common Causes
Several other conditions can produce secondary hyperparathyroidism:
- Malabsorption disorders (celiac disease, inflammatory bowel disease, bariatric surgery): reduced absorption of calcium and vitamin D
- Severe dietary calcium deficiency: uncommon in developed countries but seen in certain populations
- Liver disease: impairs the first step of vitamin D activation (from D3 to 25-hydroxyvitamin D)
- Certain medications: anticonvulsants (phenytoin, phenobarbital) interfere with vitamin D metabolism; loop diuretics increase urinary calcium loss
How Secondary Hyperparathyroidism Is Diagnosed
The diagnosis is made by the pattern of laboratory values:
| Laboratory Value | Primary Hyperparathyroidism | Secondary Hyperparathyroidism |
|---|---|---|
| Serum calcium | Elevated | Low or low-normal (or normal in mild vitamin D deficiency) |
| PTH | Elevated or inappropriately normal | Elevated |
| Serum phosphate | Usually low | Elevated in CKD, variable otherwise |
| 25-hydroxyvitamin D | Variable | Often low |
| Kidney function (creatinine, eGFR) | Usually normal (unless late disease) | Abnormal in CKD-related cases |
| Urinary calcium | Often elevated | Usually low or normal |
Additional tests may include a 24-hour urine calcium, vitamin D level, kidney function panel, and occasionally imaging of the kidneys or bones. The goal is to identify the underlying driver of the elevated PTH so that treatment can be directed at that cause.
Treatment of Secondary Hyperparathyroidism
For vitamin D deficiency
Treatment is vitamin D replacement, typically with oral cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2). Doses vary based on the severity of deficiency but often involve a loading phase of 50,000 IU weekly for 8 to 12 weeks followed by maintenance dosing. Adequate calcium intake from diet is encouraged. Labs are rechecked after 3 to 6 months. In most cases, the PTH normalizes as the vitamin D level is restored.
For chronic kidney disease
Treatment is more complex and is typically managed by a nephrologist rather than a general physician. The strategy combines several components:
- Dietary phosphate restriction: avoiding high-phosphate foods and beverages
- Phosphate binders: medications taken with meals that bind dietary phosphate and prevent its absorption (calcium-based binders such as calcium acetate, or non-calcium-based binders such as sevelamer and lanthanum)
- Active vitamin D analogs: calcitriol, paricalcitol, or doxercalciferol, which provide the activated form of vitamin D that the damaged kidneys can no longer produce
- Calcimimetics (cinacalcet, etelcalcetide): medications that bind to the calcium-sensing receptor on the parathyroid glands and reduce PTH secretion
The goal is to keep PTH, calcium, and phosphate within target ranges appropriate to the stage of kidney disease. Parathyroid surgery is occasionally needed in patients with severe, treatment-refractory tertiary hyperparathyroidism, particularly in dialysis patients with markedly enlarged glands and symptoms that have not responded to medical therapy. This is called subtotal parathyroidectomy and is a specialized operation performed at centers experienced with end-stage renal disease.
Tertiary hyperparathyroidism is the situation in which chronically stimulated parathyroid glands in secondary disease develop autonomous function and no longer respond to correction of the underlying cause. A kidney transplant recipient whose kidney function has been restored but whose PTH remains markedly elevated, with now-elevated calcium, has likely developed tertiary hyperparathyroidism. This condition often requires surgical treatment because the glands have become autonomous despite the original stimulus being removed.
What Patients Need to Understand
If you have been told your PTH is elevated and you have chronic kidney disease or known vitamin D deficiency, you do not have the same disease as a patient with a parathyroid adenoma. Surgery is not typically the answer. Your PTH is elevated because it is supposed to be, given what is happening elsewhere in your body.
The treatment is directed at the underlying cause. For vitamin D deficiency, that is often simple supplementation. For CKD, it involves coordinated medical management that should be overseen by a nephrologist with experience in mineral and bone disease. In either case, the goal is to normalize the calcium, phosphate, and PTH balance without removing the parathyroid glands themselves.
The Bottom Line
Secondary hyperparathyroidism is a response to a problem, not a problem with the glands themselves. The distinction between primary and secondary disease is essential because it determines whether surgery is the appropriate treatment (for primary disease) or whether medical management of the underlying cause is what is needed (for secondary disease).
If your PTH is elevated, the next question is always: why? The answer to that question, not the PTH level itself, determines the appropriate next step.
References
- Lau WL, et al. AAES Guidelines for the Definitive Surgical Management of Secondary and Tertiary Renal Hyperparathyroidism. Ann Surg. 2022.
- National Kidney Foundation — Hyperparathyroidism in CKD.
- American Association of Endocrine Surgeons — Patient Resources.
This article was written by John P. Sabra, MD FACS and is intended for patient education only. It does not constitute medical advice and does not replace a consultation with your physician. Individual patient circumstances, laboratory findings, and the underlying cause determine the appropriate management for every patient.
More from the Parathyroid Disease series
Ready to Talk to a Specialist?
A thyroid specialist can review your specific results, answer your questions, and help you understand exactly what your next steps should be. The ATLAS network connects you with experienced thyroid and parathyroid expert physicians who focus on thyroid disease.
Find a Thyroid Specialist Near You →